Thursday, September 21, 2023

With the introduction of the first recombinant protein therapeutic in 1982, the market for biologics started to grow at high rates, resulting in the demand for adequate production technologies. In 2005, the small start-up company Cellca GmbH was founded with the mission to fulfill the still unmet need for an efficient cell line development and bioprocessing platform that is tailor-made for the requirements of the biopharmaceutical industry. This talk will tell the success story of Cellca and its cell line development technology from the beginning over the acquisition by Sartorius in 2015 until today. It will show how the platform was and is continuously improved to solve challenges like the need to reduce time-to-market, development, and manufacturing costs, as well as the increasing molecule complexity and product quality demands.

Download the Document

* denotes a required field

Please fill out the information below. If you are already registered, login and this information will be filled out for you.

Name *
Please enter your first and last name.
Company/Institution *
Please enter the name of the company or institution you work at.
Address *
Please enter your mailing address.
Email Address *
Please enter the e-mail address you would like to be contacted at.
Work Phone Number *
Please enter the phone number you would like to be contacted at.

By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.